

VISCO-3™ Sodium Hyaluronate Coding Reference Guide



VISCO-3™ Sodium Hyaluronate is a sterile, viscoelastic non-pyrogenic solution of purified, high molecular weight sodium hyaluronate (hyaluronan). One mL of VISCO-3 contains 10 mg of sodium hyaluronate (hyaluronan) dissolved in a physiological saline (1.0% solution), and each injection contains 2.5mL of volume. Each treatment course consists of three injections given in a weekly cadence, with each injection containing 25mg of sodium hyaluronate.

HCPCS (Healthcare Common Procedure Coding System)

Code	Description
J7321	Hyaluronan or derivative, Hyalgan, Supartz or VISCO-3, for intra-articular injection, per dose <i>(effective for dates of service on or after April 1, 2021)</i>

*NOTE: VISCO-3 Sodium Hyaluronate was appropriately reported using HCPCS Level II code J7333 (Hyaluronan or derivative, VISCO-3, for intra-articular injection, per dose) for dates of service occurring July 1, 2020 - March 31, 2021.

CPT® (Current Procedural Terminology) Codes

Code	Description
20610	Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance
20611	Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); with ultrasound guidance, with permanent recording and reporting

CPT and HCPCS Modifiers

Modifier	Description
EJ	Subsequent claims for a defined course of therapy, e.g., EPO, sodium hyaluronate, infliximab (Report modifier EJ for subsequent injections of the product)
LT	Left side (used to identify procedures performed on the left side of the body)
RT	Right side (used to identify procedures performed on the right side of the body)
50	Bilateral Procedure
59	Distinct Procedural Service (indicates that a procedure or service was distinct or independent from other non-E/M services performed on the same day)

Sample ICD-10-CM Diagnosis Codes

Code	Description
M17.0	Bilateral primary osteoarthritis of knee
M17.10	Unilateral primary osteoarthritis, unspecified knee
M17.11	Unilateral primary osteoarthritis, right knee
M17.12	Unilateral primary osteoarthritis, left knee
M17.2	Bilateral post-traumatic osteoarthritis of knee
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee
M17.31	Unilateral post-traumatic osteoarthritis, right knee
M17.32	Unilateral post-traumatic osteoarthritis, left knee
M17.4	Other bilateral secondary osteoarthritis of knee
M17.5	Other unilateral secondary osteoarthritis of knee
M17.9	Osteoarthritis of the knee, unspecified

UPC/NDC (Universal Product Code/National Drug Code)

Code	Description
50016-0957-21	VISCO-3 Sodium Hyaluronate (Effective 8/1/2020)

Coding and Billing for VISCO-3

- Prior authorization/pre-determination is suggested prior to administration of VISCO-3 Sodium Hyaluronate. The payer will want to review the product specifically, dosage, route of administration and medical necessity.
- It is recommended providers bill for VISCO-3 Sodium Hyaluronate showing both the J7321 HCPCS code and the NDC as reflected on the sample CMS-1500 claim form below.
- The following qualifiers are to be used when entering supplemental information for the billing of VISCO-3 Sodium Hyaluronate.

N4 National Drug Codes (NDC)
ML Milliliter

To enter supplemental information, begin at 24A on the CMS-1500 claim form by entering the qualifier and then the information. Do not enter a space between the qualifier and the number/code/information. Do not enter hyphens or spaces within the number/code. Add the supplemental information in the following order: qualifier, NDC code, one space, unit/basis of measurement qualifier, quantity. The number of digits for the quantity is limited to eight digits before the decimal and three digits after the decimal. If entering a whole number, do not use a decimal. Do not use commas.

Sample CMS-1500 Claim Form

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)											20. OUTSIDE LAB?		\$ CHARGES			
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E)											<input type="checkbox"/> YES <input type="checkbox"/> NO					
A. M17XX B. _____ C. _____ D. _____											22. RESUBMISSION CODE		ORIGINAL REF. NO.			
E. _____ F. _____ G. _____ H. _____											23. PRIOR AUTHORIZATION NUMBER					
I. _____ J. _____ K. _____ L. _____											XXXXXXXXXX					
24. A. DATE(S) OF SERVICE						B. PLACE OF SERVICE	C. EMG	D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances)			E. DIAGNOSIS POINTER	F. \$ CHARGES	G. DAYS OR UNITS	H. EPSTD Family Plan	I. ID. QUAL.	J. RENDERING PROVIDER ID. #
MM	DD	YY	MM	DD	YY	SERVICE		CPT/HCPCS	MODIFIER							
XX	XX	XX	XX	XX	XX	11		20610	LT		A	XXX XX	1		NPI	XXXXXXXXXX
N450016095721 ML2.5																
XX	XX	XX	XX	XX	XX	11		J7321	LT		A	XXX XX	1		NPI	XXXXXXXXXX
															NPI	

- Field 21: Enter the ICD-10-CM diagnosis code(s)
 Field 23: Enter the payer prior authorization number received during the benefit investigation
 Field 24A: Enter the product supplemental information (qualifier, NDC, measurement qualifier, quantity) along with the date of service
 Field 24D: Enter the CPT/HCPCS code(s) for the services/products provided and any appropriate modifiers
 Field 24E: Enter the diagnosis code reference letter (pointer) from field 21 to relate the date of service and the procedures performed to the primary diagnosis.
 Field 24F: Enter the charge amount for each listed service.
 Field 24G: Enter the number of days or units.

Medicare Guidance for Injection Services

Where the sole purpose of an office visit was for the patient to receive an injection, payment may be made only for the injection service (if it is covered). Conversely, injection services included in the Medicare Physician Fee Schedule (MPFS) are not paid for separately if the physician is paid for any other physician fee schedule service furnished at the same time. Payment may be made for those injection services only if no other physician fee schedule service is being paid. All injection claims must include the specific name of the drug and dosage. Identification of the drug enables payment for the services.

Source: Medicare Claims Processing Manual, 20.5.7 – Injection Services

Hospital Outpatient and Ambulatory Surgical Center (ASC)

CPT® Code	Description	Ambulatory Payment Classification	OPPS Status Indicator	ASC Payment Indicator
20610	Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance	5441	T	P3
20611	Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); with ultrasound guidance, with permanent recording and reporting	5441	T	P3
J7321	Hyaluronan or derivative, Hyalgan, Supartz or VISCO-3, for intra-articular injection, per dose	NA	N	N1

OPPS - Medicare's Outpatient Prospective Payment System.

APC: N/A - Not applicable; 5441 - Level 1 Nerve Injections

Status Indicators: N - Payment is packaged into payment for other services; no separate APC payment. T - Multiple procedure reduction applies.

Payment Indicators: N1 - Packaged service/item; no separate payment. P3 - Payment based on Medicare's Physician Fee Schedule (MPFS) non-facility Practice Expense (PE) Relative Value Units (RVUs).

For further assistance with reimbursement questions, contact the Zimmer Biomet Reimbursement Hotline at 866-946-0444 or reimbursement@zimmerbiomet.com, or visit our reimbursement web site at zimmerbiomet.com/reimbursement.

Current Procedural Terminology (CPT®) copyright 2020 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

Zimmer Biomet Coding Reference Guide Disclaimer

Providers, not Zimmer Biomet, are solely responsible for ensuring compliance with Medicare, Medicaid and all other third-party payer requirements, as well as accurate coding, documentation and medical necessity for the services provided. Before filing claims, providers should confirm individual payer requirements and coverage/medical policies. The information provided in this document is not legal or coding advice; it is general reimbursement information for reference purposes only. It is important to note that Zimmer Biomet provides information obtained from third-party authoritative sources and such sources are subject to change without notice, including as a result in changes in reimbursement laws, regulations, rules and policies. This information may not be all-inclusive and changes may have occurred subsequent to publication of this document. This document represents no promise or guarantee by Zimmer Biomet regarding coverage or payment for products or procedures by Medicare or other payers. Inquiries can be directed to the provider's respective Medicare Administrative Contractor, or to appropriate payers. Zimmer Biomet specifically disclaims liability or responsibility for the results or consequences of any actions taken in reliance on information in this guide.

For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert and www.zimmerbiomet.com.